{"symbol": "ADXS", "name": "Advaxis", "next_earnings_utc": 1591876800, "next_earnings_period_start_date_utc": 1580428800, "next_earnings_period_end_date_utc": 1588204800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.15, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "advaxis.com", "year_founded": 2002, "street_address": "305 College Road East", "city": "Princeton", "state": "NJ", "zipcode": "08540", "country": "United States", "phone_number": "609-452-9813", "short_description": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States.", "long_description": "Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 47088111, "total_enterprise": 19577111, "number_of_employees": 35, "outstanding_shares": 60245793, "eps": -1.381793, "diluted_eps": -1.381793, "earnings_from_cont_operations": -37286000, "gross_profit": 1198000, "cash": 34156000, "total_debt": 6645000, "total_revenue": 1198000, "cash_from_operations": -31966000, "net_income": -37286000, "ebitda": -32717000, "year_low_stock_price": 0.2051, "year_high_stock_price": 2.95, "seekingalpha_follower_count": 11019, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/ADXS.png"}